 | • レポートコード：MRC2303I0119 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、111ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査レポートでは、世界の耳感染症治療市場規模が、2021年に10,671.91百万ドルとなり、予測期間中に年平均5.19%で成長すると予測しています。本レポートは、耳感染症治療の世界市場について調べ、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、感染症別（内耳炎、中耳炎、外耳炎）分析、原因別（ウィルス感染、細菌感染）分析、種類別（投薬、手術）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来の動向などを以下の構成でまとめています。また、Olympus Corporation、American Diagnostic Corporation、Pfizer PLC、Novartis AG、Grace Medical、Sanofi SA、GlaxoSmithKline PLC、Johnson & Johnson、Cipla Ltd、Otonomy Inc.、Medtronic PLC、Torque Pharmaなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の耳感染症治療市場規模：感染症別 - 内耳炎治療の市場規模 - 中耳炎治療の市場規模 - 外耳炎治療の市場規模 ・世界の耳感染症治療市場規模：原因別 - ウィルス感染における市場規模 - 細菌感染における市場規模 ・世界の耳感染症治療市場規模：種類別 - 投薬治療の市場規模 - 手術治療の市場規模 ・世界の耳感染症治療市場規模：地域別 - 北米の耳感染症治療市場規模 アメリカの耳感染症治療市場規模 カナダの耳感染症治療市場規模 メキシコの耳感染症治療市場規模 … - ヨーロッパの耳感染症治療市場規模 ドイツの耳感染症治療市場規模 イギリスの耳感染症治療市場規模 フランスの耳感染症治療市場規模 … - アジア太平洋の耳感染症治療市場規模 中国の耳感染症治療市場規模 日本の耳感染症治療市場規模 インドの耳感染症治療市場規模 … - 中東/南米の耳感染症治療市場規模 南アフリカの耳感染症治療市場規模 ブラジルの耳感染症治療市場規模 アルゼンチンの耳感染症治療市場規模 … - その他地域の耳感染症治療市場規模 ・競争状況 ・市場機会・将来の動向 |
The ear infection treatment market was valued at USD 10,671.91 million in 2021, and it is expected to register a CAGR of 5.19% during the forecast period.
The COVID-19 outbreak impacted every aspect of the healthcare industry, including the market for ear infection drugs and surgeries, as there are significant disruptions to businesses and economic activities worldwide. According to a study titled ‘Covid-19 and Ear Surgery: Treatment Strategies and Triage during the Post-lockdown Period’, in 2020, ear surgery was a potential source of infection for healthcare workers. The report stated that triage of cases with ear disease requiring surgical intervention is still a must until vaccines are made readily available to the general population and healthcare workers on a large scale. This condition during the pandemic has impacted the ear infection market significantly.
An ear infection occurs when a bacterial or viral infection affects the inner, middle, or outer ear. Ear infections can be painful because of inflammation and fluid buildup in the ear. Acute ear infections can cause mild pain and discomfort in the ear. However, chronic cases can cause severe pain, loss of body balance, drainage of fluids from the ear, headache, and even hearing loss in some cases.
Other factors like unclean and unhealthy environment also increase the risk of ear infection, thus boosting the ear infection treatment market.
Ear infections can sometimes cause hearing loss due to inflammation and fluid buildup in the area behind the eardrum. According to the World Health Organization (WHO), nearly 2.5 billion people are projected to have some degree of hearing loss, and at least 700 million will require hearing rehabilitation by 2050. However, the high costs of surgical procedures in severe cases have been restraining the growth of the market.
Ear Infection Treatment Market Trends
The Middle Ear Infection Segment is Expected to Show a High Growth Rate During the Forecast Period
An ear infection, called acute otitis media (AOM), is an infection of the middle ear, the air-filled space behind the eardrum that contains the tiny vibrating bones of the ear. Children are more likely than adults to get ear infections. A 2021 study titled “Ear tubes or antibiotics for repeat infections in children”, reported that ear infections are among the most common illnesses in US children. They occur when bacteria or viruses infect the area behind the eardrum called the middle ear. Parts of the middle ear become swollen or blocked, trapping fluid behind the eardrum, leading to pressure and pain and affecting hearing.
Another study titled “What is the incidence and prevalence of acute otitis media (AOM) in the US?”, published in September 2019, reported that the incidence of middle ear effusion episodes is approximately 48% at age six months, 79% at age 1 year, and 91% at age 2 years. The peak incidence of the disease is in children aged between 3 and 18 months. As per a 2021 report titled ‘Acute Otitis Media’, approximately 80% of all children will experience a case of otitis media during their lifetime, and between 80% and 90% of all children will have otitis media with an effusion before school age.
Furthermore, a study titled ‘Inactivation and sensitization of Pseudomonas aeruginosa by microplasma jet array for treating otitis media’, published in 2021, reported the feasibility and potential of a microplasma jet array as a treatment method for otitis media from in vitro, driving the market. Hence, these factors are expected to drive the market over the forecast period.
North America Dominates the Market and is Expected to Continue the Trend During the Forecast Period
The ear infection treatment market in the United states is driven by the increasing number of ear infections, growing behavioral risk factor of smoking, and increasing product launches for treating ear infections.
According to an article published by the National Institute on Deafness and Other Communication Disorders in March 2021, five out of six children in the country experience ear infection by 3 years of age. Thus, the high incidence rate of ear infection in the country is projected to drive the market. According to the report titled “Acute Otitis Media”, published in March 2021, otitis media is most commonly seen between 6 and 24 months. Approximately 80% of all children experience a case of otitis media during their lifetime, and between 80% and 90% of all children will have otitis media with an effusion before school age.
In addition, the launch of new medicines for the treatment of ear infections among the country may drive the market. For instance, in August 2020, Sandoz Inc. launched the Ciprofloxacin 0.3% + Dexamethasone 0.1% otic suspension 7.5mL ear drops in the United States for the treatment of middle ear and outer ear canal bacterial infections. Thus, such product launches may positively impact the market’s growth over the forecast period. In May 2020, Smith+Nephew launched the first commercial procedure of Tula System, an in-office solution for the placement of tympanostomy tubes (commonly known as ear tubes), which are affected by ear infection, thus boosting the market. In August 2021, the United States had nearly 20 million estimated cases of acute middle ear infections, and the annual cost associated with this condition is estimated to exceed USD 4 billion.
Thus, such factors are expected to significantly boost the US ear infection treatment market during the forecast period.
Ear Infection Treatment Market Competitor Analysis
The majority of key players involved in the research and manufacturing of ear infection treatment are established in developed countries. Market leaders with more funds for research and a better distribution system have established their position in the market. Moreover, Asia-Pacific is witnessing an emergence of some small players due to the rising awareness, which has helped the market’s growth. American Diagnostic Corporation, Pfizer, Sanofi SA, Olympus Corporation, and Novartis are some of the market players.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Ear Infections
4.2.2 Increasing Exposure to Cigarette Smoke
4.3 Market Restraints
4.3.1 High Costs and Complications Related to Surgical Procedures
4.4 Industry Attractiveness – Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 Infection
5.1.1 Inner Ear Infection
5.1.2 Middle Ear Infection
5.1.3 Outer Ear Infection
5.2 Cause
5.2.1 Viral Infection
5.2.2 Bacterial Infection
5.3 Type
5.3.1 Medication
5.3.1.1 Antibiotics
5.3.1.2 Analgesics
5.3.1.3 AntiViral
5.3.2 Surgery
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Olympus Corporation
6.1.2 American Diagnostic Corporation
6.1.3 Pfizer PLC
6.1.4 Novartis AG
6.1.5 Grace Medical
6.1.6 Sanofi SA
6.1.7 GlaxoSmithKline PLC
6.1.8 Johnson & Johnson
6.1.9 Cipla Ltd
6.1.10 Otonomy Inc.
6.1.11 Medtronic PLC
6.1.12 Torque Pharma
7 MARKET OPPORTUNITIES AND FUTURE TRENDS